» Articles » PMID: 38426692

Immunological Pathways in Viral Hepatitis-induced Hepato-cellular Carcinoma

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is a serious neoplastic disease with increasing incidence and mortality, accounting for 90% of all liver cancers. Hepatitis viruses are the major causative agents in the development of HCC. Hepatitis A virus (HAV) primarily causes acute infections, which is associated with HCC to a certain extent, as shown by clinicopathological studies. Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections lead to persistent liver inflammation and cirrhosis, disrupt multiple pathways associated with cellular apoptosis and proliferation, and are the most common viral precursors of HCC. Mutations in the HBV X protein (HBx) gene are closely associated with the incidence of HCC, while the expression of HCV core proteins contributes to hepatocellular lipid accumulation, thereby promoting tumorigenesis. In the clinical setting, hepatitis D virus (HDV) frequently co-infects with HBV, increasing the risk of chronic hepatitis. Hepatitis E virus (HEV) usually causes acute infections. However, chronic infections of HEV have been increasing recently, particularly in immuno-compromised patients and organ transplant recipients, which may increase the risk of progression to cirrhosis and the occurrence of HCC. Early detection, effective intervention and vaccination against these viruses may significantly reduce the incidence of liver cancer, while mechanistic insights into the interplay between hepatitis viruses and HCC may facilitate the development of more effective intervention strategies. This article provides a comprehensive overview of hepatitis viruses and reviews recent advances in research on aberrant hepatic immune responses and the pathogenesis of HCC due to viral infection.

Citing Articles

Current perspectives of viral hepatitis.

Usuda D, Kaneoka Y, Ono R, Kato M, Sugawara Y, Shimizu R World J Gastroenterol. 2024; 30(18):2402-2417.

PMID: 38764770 PMC: 11099385. DOI: 10.3748/wjg.v30.i18.2402.

References
1.
Boyault S, Rickman D, De Reynies A, Balabaud C, Rebouissou S, Jeannot E . Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2006; 45(1):42-52. DOI: 10.1002/hep.21467. View

2.
Feng Z, Hensley L, McKnight K, Hu F, Madden V, Ping L . A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature. 2013; 496(7445):367-71. PMC: 3631468. DOI: 10.1038/nature12029. View

3.
Cho J, Baek W, Yang S, Chang J, Sung Y, Suh M . HCV core protein modulates Rb pathway through pRb down-regulation and E2F-1 up-regulation. Biochim Biophys Acta. 2001; 1538(1):59-66. DOI: 10.1016/s0167-4889(00)00137-3. View

4.
Nishiyama R, Kanai T, Abe J, Hara R, Watahiki Y, Sakaguchi T . Hepatocellular carcinoma associated with autoimmune hepatitis. J Hepatobiliary Pancreat Surg. 2004; 11(3):215-9. DOI: 10.1007/s00534-003-0878-z. View

5.
Wang X, Forrester K, Yeh H, Feitelson M, Gu J, Harris C . Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A. 1994; 91(6):2230-4. PMC: 43344. DOI: 10.1073/pnas.91.6.2230. View